S14G-HN (Humanin Analog)
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
S14G-HN is a superpotent synthetic analog of humanin, marketed for neuroprotection, cardiac and kidney protection, and general anti-aging cytoprotection. The case rests almost entirely on animal and cell studies; human evidence is low or speculative, with no established human safety profile. Its anti-apoptotic mechanism also raises an unresolved theoretical cancer concern. Not an approved drug in the US, and supply is unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
S14G-HN is a supercharged version of humanin, a naturally occurring 24-amino-acid peptide that your mitochondria produce as a stress-protection signal. Humanin was discovered in 2001 in brain tissue from an Alzheimer's patient, and it was the first peptide found to be encoded by mitochondrial DNA (rather than the DNA in the cell nucleus). The S14G modification — swapping a single amino acid at position 14 — makes the peptide roughly 1,000 times more potent than the natural version. S14G-HN is the standard research form used in virtually all preclinical studies of humanin biology.
How it works in the body
A modified humanin peptide with a serine-to-glycine substitution at position 14 that makes it 1000x more potent. It activates the same FPRL1 and CNTFR/WSX-1/gp130 receptor systems as natural humanin, providing amplified neuroprotective, anti-apoptotic, and cytoprotective signaling.
Research overview
S14G-HN protects cells from death through multiple mechanisms: it blocks BAX, a protein that triggers cells to self-destruct; it activates survival pathways (JAK2/STAT3, PI3K/AKT); and it can directly transform toxic amyloid-beta clumps (linked to Alzheimer's) into harmless forms. Preclinical research has expanded dramatically since 2001, with over 1,000 publications covering neuroprotection (preventing Alzheimer's-related memory loss in mice), heart protection (reducing heart attack damage in mice and pigs, preventing age-related heart scarring), metabolic benefits (improving insulin sensitivity, protecting pancreatic beta cells), and anti-aging effects (extending lifespan in C. elegans worms, improving healthspan in middle-aged mice). However, all evidence is preclinical — no human interventional trials have been conducted. Human data is limited to observational studies showing that people with naturally higher humanin levels tend to have better metabolic and cardiovascular health.
Who researches S14G-HN (Humanin Analog)?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People exploring hormone and sexual health
Researched for effects on hormone levels, sexual function, or fertility.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
Important considerations for
Those with Active cancer
ModerateMore potent humanin analog with enhanced anti-apoptotic activity. May protect tumor cells from apoptosis.
Those with Diabetes/insulin therapy (hypoglycemia risk)
ModerateHumanin analogs improve insulin sensitivity and glucose-stimulated insulin secretion. May potentiate hypoglycemia with insulin therapy.
Those who are pregnant or breastfeeding
AbsoluteNo human safety data. Potent anti-apoptotic signaling via STAT3 pathway.
Safety & interactions
Do not use if
Active cancer
ModerateMore potent humanin analog with enhanced anti-apoptotic activity. May protect tumor cells from apoptosis.
Diabetes/insulin therapy (hypoglycemia risk)
ModerateHumanin analogs improve insulin sensitivity and glucose-stimulated insulin secretion. May potentiate hypoglycemia with insulin therapy.
General cautions
Pregnancy
AbsoluteNo human safety data. Potent anti-apoptotic signaling via STAT3 pathway.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(8)
Rated by level of concern
No established human safety profile
HighClinicalTrials.gov: NCT03431844, NCT06105229, NCT06125249, NCT07678073 (none involve dosing humanin or an analog)
Potential cancer promotion via anti-apoptotic effects
ModeratePMID 32444831; PMID 30582721; PMID 37552125
Research-grade product quality and purity concerns
HighNo FDA approval or marketing application for humanin or S14G-humanin
Modulation of IGF-1/IGFBP-3 axis
ModeratePMID 26216267; PMID 30184438; PMID 27082450
Additive bleeding risk due to antiplatelet effects
ModeratePMID 32174022
Short and poorly characterized plasma half-life
ModeratePMID 23836030; PMID 37351170; PMID 31655204
Injection site reactions
LowNo human dosing data; general subcutaneous peptide class expectation
Unknown effects on immune surveillance and inflammation
TheoreticalPMID 17084101 (FPRL1 immune biology); PMID 34605740; PMID 34965184
Interaction summary(7)
Rated by direction with this peptide
Antiplatelet agents and anticoagulants (aspirin, clopidogrel, DOACs, heparin)
CautionModerateHNG itself inhibits platelet activation and thrombus formation in preclinical models, so additive bleeding risk with antiplatelet or anticoagulant therapy is mechanistically demonstrated even though never quantified in humans.
PMID 32174022
Cytotoxic chemotherapy and other pro-apoptotic anticancer agents
CautionModerateS14G-HN's central action is blocking Bax/Bid-mediated apoptosis, and humanin has been shown to promote tumor progression in experimental triple-negative breast cancer, so it could plausibly blunt the intended cytotoxic effect or support chemoresistance.
PMID 32444831; PMID 30582721
Bortezomib and chemotherapy-induced off-target toxicity (bone, germ cell)
ProtectiveLowHumanin protected against bortezomib-induced bone growth impairment and HNG protected germ cells and leucocytes from chemotherapy-induced apoptosis in rodents - a genuine protective signal for off-target tissue, which nonetheless coexists with the tumor-protection concern above.
PMID 24586107; PMID 26384090
Insulin, sulfonylureas and other glucose-lowering agents
CautionTheoreticalHumanin enhances peripheral insulin action centrally in rodents, so additive hypoglycemia with insulin or secretagogues is a reasonable mechanistic concern with no human data behind it.
PMID 19623253
IGF-1, growth hormone and GH secretagogues
CautionTheoreticalHumanin binds IGFBP-3 and functionally interfaces with IGF-I signaling, so co-administration with agents that raise IGF-1 could shift free IGF-1 and growth signaling in unpredictable directions.
PMID 27082450; PMID 26216267
Statins and lipid-lowering therapy
SynergisticTheoreticalGly[14]-humanin inhibited ox-LDL uptake and stimulated cholesterol efflux in macrophages, a direction complementary to statin therapy, but this is cell-level data only with no outcome evidence.
PMID 27815075
Nephrotoxic agents (cisplatin, aminoglycosides) and sepsis-associated AKI
ProtectiveTheoreticalS14G-HN reduced injury in rodent septic AKI and diabetic nephropathy models, suggesting a protective direction against renal insults; note the cited evidence is sepsis/diabetes-driven, not direct drug-nephrotoxicity models, and no co-administration study with a nephrotoxic drug has been done.
PMID 39332154; PMID 37119975
Known risks(8)
No established human safety profile
HighS14G-HN has never been administered to humans in a controlled clinical trial. All safety data is extrapolated from cell culture and animal studies. Long-term effects of exogenous S14G-HN supplementation in humans are completely unknown. Systematic toxicology studies have not been published. The absence of evidence is not evidence of absence of harm.
Potential cancer promotion via anti-apoptotic effects
HighS14G-HN inhibits BAX-mediated apoptosis, a key tumor suppressor mechanism. Preclinical studies have shown humanin promotes tumor progression in triple-negative breast cancer (Pena et al. 2020), facilitates chemoresistance in glioblastoma (2023), and activates integrin alphaV-TGFbeta axis promoting glioblastoma progression (2024). While no increase in tumor incidence has been observed in long-term animal studies, the theoretical risk of enhanced cancer cell survival and chemoresistance is significant. Contraindicated in individuals with active malignancy or cancer history.
Research-grade product quality and purity concerns
HighAll commercially available S14G-HN is research-grade, not manufactured under pharmaceutical GMP standards. Purity claims are seller-stated and may not be independently verified. Impurities, degradation products, endotoxins, and synthesis byproducts could cause immunogenic reactions, injection site infections, or systemic toxicity.
Modulation of IGF-1/IGFBP-3 axis
ModerateS14G-HN binds IGFBP-3 and decreases plasma IGFBP-3 levels (to approximately 80% of baseline within 3 hours in animal studies). This could alter IGF-1 bioavailability with unpredictable effects on growth factor signaling, glucose metabolism, and potentially cancer biology. The IGF-1 axis is complex and disruption may have both beneficial and harmful consequences.
Additive bleeding risk due to antiplatelet effects
ModerateRen et al. (2020) demonstrated that S14G-HN inhibits platelet aggregation and thrombus formation via microtubule stabilization. While bleeding time was not prolonged in the mouse study, combination with anticoagulants or antiplatelet drugs could theoretically increase bleeding risk.
Short and poorly characterized plasma half-life
ModerateS14G-HN has a plasma half-life of only ~30 minutes in mice. The pharmacokinetics are species-dependent (>4 hours in rats) and heavily influenced by IGFBP-3 levels, making human pharmacokinetics unpredictable. Biodistribution studies show limited brain and heart penetration despite efficacy at those sites, suggesting the pharmacokinetic-pharmacodynamic relationship is poorly understood.
Injection site reactions
Low-ModerateAs with all subcutaneously administered peptides, injection site reactions including redness, swelling, pain, and irritation are expected. Risk is amplified by non-pharmaceutical grade products and improper injection technique.
Unknown effects on immune surveillance and inflammation
S14G-HN modulates multiple inflammatory pathways (JAK/STAT, NF-kB, TLR4, NLRP3, TNF-alpha, interleukins) and has broad anti-apoptotic activity. While preclinical studies show anti-inflammatory benefits, the effects of sustained exogenous supplementation on immune surveillance, infection response, autoimmune regulation, and tissue homeostasis in humans are entirely unknown.
Drug interactions(7)
Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel, DOACs)
Theoretical additive bleeding risk. S14G-HN inhibits platelet aggregation and thrombus formation via microtubule stabilization (Ren et al. 2020). While bleeding time was not prolonged in mouse studies, the antiplatelet mechanism could synergize with standard anticoagulant or antiplatelet therapy, increasing hemorrhagic risk.
Insulin and insulin secretagogues (sulfonylureas, meglitinides)
Theoretical additive hypoglycemia risk. S14G-HN enhances insulin sensitivity via central STAT3 signaling, peripheral AKT activation, and improved beta-cell function. Combined use with insulin or insulin secretagogues could potentiate blood sugar lowering beyond intended levels. S14G-HN has been shown to reduce blood glucose and elevate serum insulin in diabetic mice.
Chemotherapy agents (general)
Complex, context-dependent interaction. S14G-HN's anti-apoptotic properties could theoretically reduce chemotherapy efficacy against tumor cells by inhibiting drug-induced apoptosis. Humanin facilitated chemoresistance in glioblastoma cells and promoted glioblastoma progression via integrin alphaV-TGFbeta. Conversely, Bhavnani et al. 2015 showed S14G-HN enhanced cyclophosphamide-induced cancer suppression while protecting normal cells. The net effect may depend on tumor type and chemotherapy mechanism. Use with active chemotherapy is inadvisable without oncologist guidance.
IGF-1 and growth hormone therapies
S14G-HN binds IGFBP-3 and decreases plasma IGFBP-3 levels, which could increase free IGF-1 bioavailability. This may amplify or interfere with exogenous IGF-1 or GH therapy effects. The interaction with the GH/IGF-1 axis is bidirectional and complex.
JAK inhibitors (tofacitinib, baricitinib, ruxolitinib)
Theoretical antagonistic interaction. S14G-HN signals through JAK2/STAT3 pathway via the CNTFR/WSX-1/gp130 receptor complex. JAK inhibitors could block S14G-HN signaling, reducing or abolishing its cytoprotective effects.
Anti-inflammatory and immunosuppressive agents (corticosteroids, biologics)
Potential additive immunosuppression. S14G-HN suppresses multiple inflammatory pathways including TLR4/NF-kB, NLRP3 inflammasome, and production of TNF-alpha, IL-1beta, IL-6, and other cytokines. Combined use with corticosteroids or biologic immunosuppressants could result in excessive immune suppression, although this has not been studied.
Other mitochondrial-derived peptides (MOTS-c, SHLP2, SHLP6)
No documented interactions, but combined use of multiple MDPs could have unpredictable synergistic effects on mitochondrial function, apoptosis regulation, and metabolic signaling. S14G-HN and SHLP2 share chaperone-like activity and overlapping downstream pathways.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 1000
- Human Studies
- 0
All efficacy data for S14G-HN comes from cell culture and animal (primarily mouse and rat) models, with one large-animal study in pigs (Sharp et al. 2020). Human data is limited to observational and correlational studies measuring endogenous humanin levels as biomarkers in aging, Alzheimer's disease, AMD, gestational diabetes, and metabolic disease — none involving administration of exogenous S14G-HN. Endogenous humanin levels decline with age, are elevated in centenarian offspring (Barzilai/Cohen labs), are approximately 37% lower in AMD patients than age-matched controls, and correlate positively with ovarian reserve in follicular fluid. The preclinical evidence is robust and consistent across neuroprotection, cardioprotection, metabolic regulation, retinal protection, renal protection, and anti-inflammatory applications spanning multiple independent laboratories worldwide. However, the complete absence of human interventional data means no clinical efficacy or safety profile has been established.
Researched for(9)
Rated by confidence in the evidence
Neuroprotection against Alzheimer's disease pathology
LowMultiple rodent studies show cognitive benefit, no human trials, and two related papers were retracted.
PMID 11739234; PMID 19463756; PMID 21264226; PMID 21993310; retractions PMID 27033171, PMID 27282139
Cardioprotection and reduction of ischemia/reperfusion injury
LowReduced infarct size in mice and pigs, but benefit disappeared with longer ischemia; no human trials.
PMID 20651283; PMID 32760857; PMID 34506248
Anti-inflammatory effects across multiple tissues
LowReduced inflammation in small rodent and cell studies across several tissues; no human data yet.
PMID 34965184; PMID 34605740; PMID 34459932; PMID 39332154
Improved insulin sensitivity and metabolic regulation
LowImproved insulin sensitivity in animal studies; human data are observational correlations only, not treatment trials.
PMID 19623253; PMID 37119975; PMID 35536048; human observational PMID 35683389, PMID 34351816
Retinal protection against oxidative and inflammatory damage
LowProtective effects seen mostly in cell culture studies; very limited animal testing, no human data.
PMID 28726777; PMID 32768357; PMID 34459932; PMID 30381074
Renal protection in ischemia/reperfusion and sepsis
LowProtective in animal models of kidney injury and sepsis; human evidence is observational only.
PMID 39332154; PMID 37119975; PMID 22820173; PMID 36119052; observational NCT06105229, NCT06125249
Cerebrovascular protection in stroke
LowReduced stroke damage in multiple rodent models; no human stroke trials exist yet.
PMID 16960089; PMID 29999240
Reproductive and fertility protection
LowProtected reproductive tissue in animal studies; found naturally in human sperm, no clinical trials.
PMID 26384090; PMID 40639309; PMID 20542501; review PMID 34626748
Lifespan and healthspan extension (model organisms)
SpeculativeExtended lifespan in one worm study; conflicting animal evidence exists, highly preliminary overall.
PMID 32575074; counter-evidence PMID 30058454; review PMID 35499074
Benefits(9)
Neuroprotection against Alzheimer's disease pathology
Hashimoto et al. 2001 (PNAS) — Discovery paper showing humanin/S14G-HN rescues neuronal cell death from multiple AD genes and Abeta. Tajima et al. 2005 (J Neurosci Res) — 50 pmol S14G-HN ICV prevented Abeta-induced spatial memory impairment in mice. Zhang et al. 2012 (Pharmacol Biochem Behav) — 3 months of S14G-HN improved cognition, reduced Abeta plaques, and suppressed neuroinflammation in APPswe/PS1dE9 mice. Ma et al. 2009 (Peptides) — S14G-HN protected against Abeta-induced LTP inhibition in mouse hippocampal slices. Xu et al. 2009 (Neurochem Int) — S14G-HN protected PC12 cells from Abeta by preventing mitochondrial dysfunction.
Cardioprotection and reduction of ischemia/reperfusion injury
Muzumdar et al. 2010 (Arterioscler Thromb Vasc Biol) — Acute S14G-HN treatment attenuated myocardial infarct size in mice. Sharp et al. 2020 (JACC Basic Transl Sci) — S14G-HN reduced infarct size in a porcine (large animal) model. Zhao et al. 2023 (Heliyon) — S14G-HN conferred cardioprotection against chronic adrenergic and pressure overload-induced heart failure in mice, reducing inflammatory infiltration, myocardial fibrosis, and cardiomyocyte apoptosis via TGF-beta/Smads pathway. Li et al. 2022 (Bioengineered) — S14G-HN protected against streptozotocin-induced diabetic cardiac dysfunction.
Anti-inflammatory effects across multiple tissues
Peng et al. 2018 (IUBMB Life) — S14G-HN suppressed TNF-alpha, IL-1beta, IL-6, and MCP-1 production in murine MCAO stroke model and inhibited VCAM-1 and ICAM-1 expression. Wang et al. 2023 (Aging) — S14G-HN ameliorated ovalbumin-induced airway inflammation in asthma model mice via TLR4/NF-kB/Egr-1 pathway inhibition. Chen et al. 2021 (Bioengineered) — S14G-HN suppressed LPS-induced inflammation in human dental pulp cells via TLR4/MyD88/NF-kB pathway. Liu et al. 2021 (Inflamm Res) — S14G-HN protected retinal endothelial cells from UV-B-induced NLRP3 inflammasome activation.
Improved insulin sensitivity and metabolic regulation
Muzumdar et al. 2009 (PLoS One) — Central humanin infusion improved overall insulin sensitivity via hypothalamic STAT3. Kuliawat et al. 2013 (PLoS One) — Humanin improved survival of pancreatic beta cells. Yuan et al. 2022 (Gynecol Endocrinol) — S14G-HN reduced blood glucose, elevated serum insulin, and improved lipid metabolism in gestational diabetes mice, while increasing fetus survival and reducing placental ER stress. Yin et al. 2017 (Neurosci Lett) — S14G-HN alleviated insulin resistance and increased autophagy in neurons of APP/PS1 transgenic mice.
Retinal protection against oxidative and inflammatory damage
Nashine et al. 2017 (Cell Death Dis) — S14G-HN protected AMD transmitochondrial cybrids from mitochondrial and cellular damage. Liu et al. 2021 (Inflamm Res) — S14G-HN inhibited UV-B-induced NLRP3/TXNIP signaling and IL-1beta/IL-18 release in retinal endothelial cells via Egr-1 inhibition. Sreekumar et al. 2020 (Aging) — S14G-HN was 10-fold more potent than native humanin in protecting RPE cells from oxidative stress, promoting mitochondrial biogenesis.
Renal protection in ischemia/reperfusion and sepsis
Zhang et al. 2024 (Biochem Biophys Res Commun) — S14G-HN protected against septic acute kidney injury by improving renal function, reducing tubular injury, and decreasing pro-inflammatory cytokines and oxidative stress. Hosseini et al. 2025 (Research Square preprint) — S14G-HN attenuated renal I/R injury by activating STAT3 and ERK1/2 signaling, preserving mitochondrial function and ATP levels.
Cerebrovascular protection in stroke
Peng et al. 2018 (IUBMB Life) — S14G-HN ameliorated cerebral infarction in murine MCAO model, suppressed inflammatory cytokines and vascular adhesion molecules, and protected brain endothelial cell survival under oxygen deprivation. Chai et al. 2017 (Neuropeptides) — S14G-HN had neuroprotective effects against oxygen-glucose deprivation/reoxygenation by reactivating JAK2/STAT3 via PI3K/AKT pathway.
Reproductive and fertility protection
Jiang et al. 2023 (Reprod Biomed Online) — [Gly14]-Humanin protected against D-galactose-induced primary ovarian insufficiency in mice, improving ovarian morphology, oestrous cycles, follicle counts, and hormone levels at 10 mg/kg. Bhavnani et al. 2015 (Endocrinology) — S14G-HN protected male germ cells and leucocytes from cyclophosphamide-induced chemotherapy toxicity.
Lifespan and healthspan extension (model organisms)
Yen et al. 2020 (Aging) — C. elegans overexpressing humanin had increased lifespan (daf-16/FOXO dependent). Twice-weekly S14G-HN treatment in middle-aged mice improved healthspan parameters including decreased visceral fat, increased lean mass, and reduced IGF-1, though lifespan was not significantly extended after 14 months of treatment.
Key studies(5)
A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice
Original research (preclinical, in vivo)Mouse study (multiple groups, Y-maze behavioral testing)Acute ICV injection with behavioral assessmentTajima H, Kawasumi M, Chiba T, Yamada M, Yamashita K, Nawa M, Kita Y, Kouyama K, Aiso S, Matsuoka M, Niikura T, Nishimoto I
Journal of Neuroscience Research
2005
At least 50 pmol of S14G-HN by intracerebroventricular injection prevented amyloid-beta-induced impairment of short-term/spatial working memory in mice. S14G-HN sustained cholinergic neurons in the basal forebrain and striata to near-normal levels. Genistein (tyrosine kinase inhibitor) blocked recovery, suggesting tyrosine kinases mediate S14G-HN's in vivo neuroprotective function. Demonstrated the S14G substitution enables effective neuroprotection at very low picomolar doses.
S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice
Original research (preclinical, in vivo)APPswe/PS1dE9 transgenic mouse cohorts3 months chronic treatmentZhang W, Zhang W, Li Z, Hao J, Zhang Z, et al.
Pharmacology Biochemistry and Behavior
2012
Chronic S14G-HN treatment for 3 months significantly improved spatial learning and memory deficits in middle-aged APPswe/PS1dE9 mice compared with vehicle controls. S14G-HN treatment significantly reduced cerebral Abeta plaque deposition, insoluble Abeta levels, and neuroinflammatory responses. Demonstrated that sustained S14G-HN administration can modify disease pathology, not just symptoms, in a chronic AD model.
The Neurovascular Protective Effect of S14G-Humanin in a Murine MCAO Model and Brain Endothelial Cells
Original research (preclinical, in vivo and in vitro)MCAO mouse model + bEnd.3 cell assaysAcute treatment with histological assessmentPeng T, Wan W, Wang J, Liu Y, Fu Z, Ma X, Li J, Sun G, Ji Y
IUBMB Life
2018
S14G-HN ameliorated cerebral infarction in a murine middle cerebral artery occlusion (MCAO) stroke model. S14G-HN suppressed production of TNF-alpha, IL-1beta, IL-6, and MCP-1 cytokines and inhibited expression of vascular adhesion molecules VCAM-1 and ICAM-1 in cortex tissue. In brain endothelial cells, S14G-HN protected cell survival under oxygen deprivation and suppressed ROS production. Established S14G-HN as a neurovascular protectant in stroke.
S14G-humanin confers cardioprotective effects against chronic adrenergic and pressure overload-induced heart failure in mice
Original research (preclinical, in vivo)HF mouse model (isoproterenol and TAC models)Chronic treatment through HF induction periodZhao Q, Cai M, Li D, Zhao B, Zhou S, Wu Z, Shi Y, Su L
Heliyon
2023
S14G-HN significantly delayed the onset of cardiac dysfunction and structural remodeling in two distinct heart failure models (adrenergic and pressure overload). S14G-HN reduced inflammatory cell infiltration, improved myocardial fibrosis, and attenuated cardiomyocyte apoptosis. The cardioprotective effects were mediated through suppression of MAPK and TGF-beta/Smads signaling pathways. Extended the cardiovascular evidence base beyond acute ischemia/reperfusion to chronic heart failure.
The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
Original research (preclinical + human observational)C. elegans, mouse cohorts, human centenarian offspring cohortUp to 14 months of S14G-HN treatment in miceYen K, Mehta HH, Kim SJ, Lue Y, Hoang J, Guerrero N, Port J, Bi Q, Navarrete G, Brandhorst S, Lewis KN, Wan J, Swerdloff R, Mattison JA, Buffenstein R, Breton CV, Wang C, Longo V, Atzmon G, Wallace D, Barzilai N, Cohen P
Aging (Albany NY)
2020
Humanin overexpression extended lifespan in C. elegans (daf-16/FOXO dependent). Twice-weekly S14G-HN treatment in middle-aged mice improved healthspan parameters (decreased visceral fat, increased lean mass, reduced IGF-1 and inflammatory markers) but did not significantly extend lifespan. Children of centenarians had higher circulating humanin than age-matched controls. Established humanin as a conserved regulator of aging across species.
Regulation & availability
Why researchers look at it
Centenarians and their offspring have naturally higher levels of humanin, the mitochondrial peptide this analog supercharges at 1,000x potency. Preclinical work across independent labs worldwide shows protection against Alzheimer's pathology, heart attack damage, beta-cell death, and retinal degeneration — with lifespan extension in C. elegans. No human interventional trials despite 20+ years of research, but if clinical development advances, S14G-HN could become a foundational mitochondrial longevity therapy.
- FDA status
- S14G-HN (Humanin Analog) is not FDA-approved for any indication and is not eligible for compounding in the US; no current eligibility under sections 503A or 503B was established. No published human interventional treatment trial or publicly confirmed IND was identified for S14G-HN. Products intended to treat disease or affect body structure or function are subject to FDA drug regulation; lack of approval does not place them outside that system.
- WADA status
- S14G-HN is not explicitly named on the 2026 WADA Prohibited List. Exogenous therapeutic use should be treated as prohibited at all times under S0's general rule for unapproved pharmacological substances, unless another section applies. A TUE would require supporting clinical evidence and satisfaction of WADA's medical criteria; lack of an approved indication alone is not an automatic exclusion stated in those criteria.
- Prescribability
- S14G-HN (Humanin Analog) is not FDA-approved and is not eligible for compounding in the US. No published human interventional treatment trial was identified for S14G-HN. It is not listed in the reviewed 503A or 503B interim categories or the final 503A bulks list, and no current lawful compounding pathway was established. Clinic offerings do not establish approval or compounding eligibility.
- Availability
- S14G-HN is not available as an approved pharmaceutical product in any jurisdiction, and there is no FDA-approved product. It does not appear in the reviewed 503A or 503B interim categories or the final 503A bulks list, and no current lawful compounding pathway was established, so it is not eligible for compounding under FDA rules. Some longevity and wellness clinics may offer humanin analogs through non-standard supply channels, but such offerings do not establish regulatory approval or compounding eligibility. Unregulated products sold online lack pharmaceutical GMP manufacturing standards, and independent third-party verification is inconsistent. There is no legitimate prescription pathway for S14G-HN in the United States or any other country.
International status
EU
Not approved
US
Not FDA-approved
Worldwide
No regulatory approval in any jurisdiction
Regulatory timeline(17)
- 2001-05Humanin discovered by Hashimoto, Niikura, and Nishimoto from an Alzheimer's disease patient brain. Published in PNAS (PMID 11371646). The S14G substitution creating a ~1000x more potent variant was identified in this same foundational work, establishing S14G-HN (HNG) as the standard research analog.
- 2003-10Ikonen et al. publish in PNAS that humanin binds IGFBP-3 and regulates the IGF-1 signaling axis, expanding S14G-HN biology beyond neuroprotection into metabolic regulation.
- 2005-01Tajima et al. publish definitive in vivo demonstration that S14G-HN prevents amyloid-beta-induced memory impairment in mice at picomolar doses, establishing the S14G variant as the preferred in vivo research tool (J Neurosci Res, PMID 15678515).
- 2006-08Benaki et al. solve the NMR solution structure of S14G-humanin (PDB ID: 2GD3), revealing an alpha-helical core (Phe6-Thr13) in lipophilic environments and flexible turn-like structures in aqueous solution (Biochem Biophys Res Commun, PMID 16945331).
- 2009-06Hashimoto et al. identify the tripartite receptor complex CNTFR-alpha/WSX-1/gp130 as a functional humanin receptor (Mol Biol Cell, PMID 19386761). Muzumdar et al. publish central regulation of insulin action by humanin (PLoS One).
- 2010-08Muzumdar et al. demonstrate acute S14G-HN therapy attenuates myocardial ischemia/reperfusion injury in mice, establishing cardioprotection as a major research axis (Arterioscler Thromb Vasc Biol, PMID 20651283).
- 2012-01Zhang et al. show chronic S14G-HN treatment reduces amyloid pathology and improves cognition in APPswe/PS1dE9 mice, demonstrating disease-modifying potential (Pharmacol Biochem Behav, PMID 21993310).
- 2013-07Gong et al. publish pharmacokinetics and tissue distribution data for S14G-HN in male rodents, establishing the ~30-minute mouse half-life and IGFBP-3 dependence of clearance (Endocrinology, PMID 23836030).
- 2017-07Nashine et al. demonstrate S14G-HN protects AMD transmitochondrial cybrids from mitochondrial damage (Cell Death Dis, PMID 28726777). Niidome et al. discover chaperone-like activity of S14G-HN (Sci Rep).
- 2018-07Peng et al. establish S14G-HN as a neurovascular protectant in murine MCAO stroke model (IUBMB Life, PMID 29999240).
- 2020-03Ren et al. discover S14G-HN inhibits platelet activation and thrombus formation (J Cell Mol Med, PMID 32174022). Sharp et al. extend cardioprotection to large animal model (porcine, PMID 32760857).
- 2020-06Yen, Cohen, Barzilai et al. publish landmark study showing humanin regulates lifespan in C. elegans and healthspan in mice, with centenarian offspring showing elevated levels (Aging, PMID 32575074).
- 2021-09S14G-HN anti-inflammatory research expands: protection against LPS-induced dental pulp cell inflammation (PMID 34605740) and UV-B-induced retinal endothelial NLRP3 activation (PMID 34459932) published.
- 2022-05Yuan et al. demonstrate S14G-HN protective effects against gestational diabetes mellitus symptoms in mice (Gynecol Endocrinol, PMID 35536048).
- 2023-07Multiple major publications: S14G-HN ameliorates asthma airway inflammation (Aging); S14G-HN protects against heart failure (Heliyon) Research scope continues expanding but remains entirely preclinical.
- 2024-09Zhang et al. demonstrate S14G-HN protection in septic acute kidney injury using advanced proteomics (Biochem Biophys Res Commun, PMID 39332154). Hosseini et al. report renoprotection in renal I/R injury (Research Square preprint).
- 2026-presentNo published human interventional treatment trial or publicly confirmed IND was identified for S14G-HN. It remains investigational, with no identified FDA-approved product or established compounding eligibility. Research remains entirely preclinical.
Sources & FAQs
Research sources(33)
- Hashimoto et al. 2001 — Humanin discovery, S14G variant identification (PNAS)
- Tajima et al. 2005 — S14G-HN prevents Abeta-induced memory impairment in mice
- Benaki et al. 2006 — Solution NMR structure of S14G-humanin (PDB 2GD3)
- Kariya et al. 2007 — Structural analysis of S14G-humanin by CD and molecular modeling
- Ma et al. 2009 — S14G-HN protects against Abeta-induced LTP inhibition
- Xu et al. 2009 — S14G-HN protects PC12 cells via mitochondrial protection
- Hashimoto et al. 2009 — Humanin receptor complex CNTFR/WSX-1/gp130
- Muzumdar et al. 2009 — Central regulation of insulin action by humanin
- Muzumdar et al. 2010 — Acute HNG therapy attenuates myocardial I/R injury
- Zhang et al. 2012 — S14G-HN improves cognition in APPswe/PS1dE9 mice
- Gong et al. 2013 — Pharmacokinetics and tissue distribution of HNG in rodents
- Bhavnani et al. 2015 — HNG protects germ cells, enhances chemo cancer suppression
- Niidome et al. 2017 — S14G-HN chaperone-like activity (Sci Rep)
- Chai et al. 2017 — S14G-HN neuroprotection via JAK2/STAT3 reactivation
- Nashine et al. 2017 — HNG protects AMD cybrids from mitochondrial damage
- Yin et al. 2017 — S14G-HN alleviates insulin resistance in APP/PS1 neurons
- Peng et al. 2018 — Neurovascular protection of S14G-HN in MCAO stroke model
- Yen et al. 2020 — Humanin regulates lifespan and healthspan (Aging)
- Ren et al. 2020 — HNG inhibits platelet activation and thrombus formation
- Sharp et al. 2020 — HNG reduces infarct size in porcine MI/R model
- Chen et al. 2021 — S14G-HN suppresses LPS-induced inflammation in dental pulp cells
- Liu et al. 2021 — S14G-HN protects retinal endothelial cells from UV-B/NLRP3
- Li et al. 2022 — S14G-HN protects against STZ-induced cardiac dysfunction
- Yuan et al. 2022 — S14G-HN protects against gestational diabetes symptoms
- Wang et al. 2023 — S14G-HN ameliorates airway inflammation in asthma (Aging)
- Zhao et al. 2023 — S14G-HN cardioprotection in heart failure (Heliyon)
- Jiang et al. 2023 — HNG protects against primary ovarian insufficiency
- Karachaliou and Livaniou 2023 — Neuroprotective action review: humanin analogues (Biology/PMC)
- Zhang et al. 2024 — S14G-HN protects in septic AKI (Biochem Biophys Res Commun)
- ADDF — Humanin and Humanin Analogs cognitive vitality report
- NIA AlzPED — S14G-HN preclinical AD evidence database
- RCSB PDB — NMR structure of S14G-humanin (PDB ID: 2GD3)
- WADA 2026 Prohibited List
Frequently asked questions(6)
Is S14G-HN the same as HNG ([Gly14]-Humanin)?
Yes, they are the exact same compound. 'S14G' describes the mutation (serine to glycine at position 14), '[Gly14]' describes the resulting structure (glycine at position 14), and 'HNG' is the shorthand abbreviation for Humanin G. All three naming conventions appear interchangeably in the scientific literature and refer to an identical 24-amino-acid synthetic peptide derived from native humanin with a single amino acid substitution at position 14.
Why is S14G-HN 1,000 times more potent than native humanin?
The precise molecular mechanism underlying the ~1000x potency increase from the S14G substitution is not fully elucidated, but NMR structural studies (PDB 2GD3) suggest that replacing the polar serine with the smaller, more flexible glycine at position 14 alters the peptide's conformational dynamics. The glycine substitution increases backbone flexibility in the C-terminal half of the peptide, which may enhance receptor binding affinity and signaling efficiency. The increased flexibility could facilitate more efficient interactions with the CNTFR/WSX-1/gp130 receptor complex and FPRL receptors. The substitution also lies adjacent to the alpha-helical region (Phe6-Thr13) and may stabilize the bioactive conformation.
Has S14G-HN been tested in humans?
No. Neither S14G-HN nor native humanin has been administered to humans in any published clinical trial. All efficacy and dosing data comes from cell culture and animal studies. Human data is limited to observational studies measuring endogenous humanin levels as biomarkers in aging, Alzheimer's disease, AMD, gestational diabetes, and metabolic disease. The complete lack of human interventional data means there is no established human safety profile, efficacy data, or validated dosing protocol.
What is the half-life of S14G-HN?
The plasma half-life of S14G-HN is approximately 30 minutes in wildtype mice but over 4 hours in rats, indicating species-dependent pharmacokinetics. The half-life is heavily influenced by IGFBP-3 binding: in IGFBP-3 knockout mice, S14G-HN has a longer half-life than in wildtype mice, suggesting circulating IGFBP-3 modulates clearance. Despite the short plasma half-life, tissue half-life appears significantly longer based on sustained efficacy with once-daily dosing in animal studies. Biodistribution after IP injection shows primary accumulation in plasma and liver.
Could S14G-HN promote cancer growth?
This is a legitimate concern. S14G-HN's anti-apoptotic properties (BAX inhibition) could theoretically protect cancer cells from programmed death. Pena et al. 2020 (Sci Rep) found humanin promoted tumor progression in triple-negative breast cancer models, and a 2023 study found humanin facilitated chemoresistance in glioblastoma. A 2024 study (Cell Death Dis) showed humanin activated integrin alphaV-TGFbeta axis and promoted glioblastoma progression. However, Bhavnani et al. 2015 found S14G-HN enhanced chemotherapy-induced cancer suppression while protecting normal cells. The effects appear cancer-type dependent. No increase in tumor incidence has been observed in long-term animal studies, but caution is warranted in individuals with active malignancy or cancer history.
How does S14G-HN relate to other mitochondrial-derived peptides like MOTS-c?
Both are mitochondrial-derived peptides (MDPs) encoded in the mitochondrial genome, but they are distinct molecules with different mechanisms. S14G-HN is an analog of humanin (24 amino acids, encoded in 16S rRNA gene MT-RNR2) that primarily signals through CNTFR/WSX-1/gp130 and FPRL receptors with anti-apoptotic effects. MOTS-c (16 amino acids, encoded in 12S rRNA gene MT-RNR1) primarily activates AMPK and translocates to the nucleus to regulate metabolic gene expression. Both decline with age and have been studied in longevity contexts. S14G-HN and SHLP2 have been shown to exhibit chaperone-like activity, suggesting overlapping proteostatic functions among some MDPs.